In clinic, the feasibility and safety of anti-CD19 CAR-T cells combined with a PD-1 inhibitors (pembrolizumab or nivolumab) in patients with R/R B-ALL and NHL were confirmed in different studies [37, 38]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.